Health and Healthcare
Should Johnson & Johnson Be Getting More Out of Q3 Earnings?
Published:
Last Updated:
Johnson & Johnson (NYSE: JNJ) reported its third-quarter financial results before the markets opened on Thursday. The company said that it had $2.05 in earnings per share (EPS) and $20.35 billion in revenue. That compared with consensus estimates of $2.03 in EPS and $20.05 billion in revenue, as well as the $1.90 per share and $19.65 billion posted in the same period of last year.
During the latest quarter, domestic sales increased 3.6%. International sales increased 3.5%, reflecting operational growth of 7.5% and a negative currency impact of 4.0%.
In terms of its segments, the company reported as follows:
- Worldwide Consumer sales of $3.4 billion for the third quarter 2018 represented an increase of 1.8% versus the prior year, consisting of an operational increase of 4.9% and a negative impact from currency of 3.1%.
- Worldwide Pharmaceutical sales of $10.3 billion for the third quarter 2018 represented an increase of 6.7% versus the prior year with an operational increase of 8.2% and a negative impact from currency of 1.5%.
- Worldwide Medical Devices sales of $6.6 billion for the third quarter 2018 represented a decrease of 0.2% versus the prior year consisting of an operational increase of 1.7% and a negative currency impact of 1.9%.
Looking ahead to the 2018 fiscal full year, the company expects to see EPS in the range of $8.13 to $8.18 and net sales between $81.0 billion and $82.4 billion.
Alex Gorsky, board chair and chief executive, commented:
We are pleased with our strong third-quarter performance, which reflects continued above-market growth in our Pharmaceutical business, accelerating sales momentum in our Consumer business and consistent progress in our Medical Devices business. I’m confident that with our collaborative and inspired J&J colleagues around the world, unique broad-based business model and strategic investments in innovation, we are well positioned for success today and into the future.
Johnson & Johnson shares closed Monday at $133.95, with a consensus analyst price target of $144.53 and a 52-week trading range of $118.62 to $148.32. Following the announcement, the stock was relatively flat at $134.00 in early trading indications Monday.
24/7 Wall St.Get Ready To Retire (Sponsored)
Start by taking a quick retirement quiz from SmartAsset that will match you with up to 3 financial advisors that serve your area and beyond in 5 minutes, or less.
Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests.
Here’s how it works:
1. Answer SmartAsset advisor match quiz
2. Review your pre-screened matches at your leisure. Check out the advisors’ profiles.
3. Speak with advisors at no cost to you. Have an introductory call on the phone or introduction in person and choose whom to work with in the future
Get started right here.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
